Sinclair IS Pharma Plc Rating Reiterated by Jefferies Group (SPH)
Sinclair IS Pharma Plc (LON:SPH)‘s stock had its “buy” rating restated by research analysts at Jefferies Group in a report released on Thursday, AnalystRatingsNetwork.com reports. They currently have a GBX 48 ($0.76) target price on the stock. Jefferies Group’s target price indicates a potential upside of 64.10% from the stock’s previous close.
Shares of Sinclair IS Pharma Plc (LON:SPH) opened at 29.00 on Thursday. Sinclair IS Pharma Plc has a 1-year low of GBX 23.15 and a 1-year high of GBX 30.418. The stock has a 50-day moving average of GBX 27.10 and a 200-day moving average of GBX 26.92.
Other equities research analysts have also recently issued reports about the stock. Analysts at N+1 Singer reiterated a “buy” rating on shares of Sinclair IS Pharma Plc (LON:SPH) in a research note to investors on Thursday. They now have a GBX 36 ($0.57) price target on the stock. Separately, analysts at Canaccord Genuity reiterated a “buy” rating on shares of Sinclair IS Pharma Plc (LON:SPH) in a research note to investors on Thursday, September 12th. They now have a GBX 38 ($0.60) price target on the stock.
One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of GBX 65.66 ($1.04).
Sinclair IS Pharma plc is a specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through surface technology and delivery systems.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.